date that HN is less frequent in an ESRD population than commonly assumed if strict clinical criteria are Background. Multiple studies suggest that hypertension-induced end-stage renal disease ( ESRD) is herit-used; many patients clinically diagnosed with HN may have undetected, treatable renal disease from other able. Identification of nephropathy susceptibility genes absolutely requires accurate phenotyping, but the clin-causes; (ii) relaxing HN phenotype criteria may erroneously include patients with glomerular diseases and ical hypertensive nephrosclerosis (HN ) phenotype is poorly characterized. We hypothesized that many secondary hypertension; (iii) reliance on HCFA 2728 diagnoses will confound identification of HN susceptipatients with HN as the indicated cause of ESRD on the Health Care Financing Administration (HCFA) bility genes; (iv) to attain adequate statistical power for genotype analysis, rigorous HN phenotyping 2728 form, fail to satisfy stringent HN phenotyping criteria.
American, 25% Caucasian) were enrolled in a study to identify HN susceptibility genes. HN was the most
The major causes of morbidity and mortality in common cause of ESRD according to HCFA 2728 developed countries are hypertension-related diseases. forms (37% prevalence). Phenotyping of randomly Recent estimates indicate that 25% of the US populaselected patients with HN from the total cohort tion, and 35% of African Americans have elevated revealed that 4/100 subjects satisfied the Schlessinger blood pressure [1] . In addition, the 1999 USRDS [2] criteria, and 28/91 African Americans met AASK report states that hypertensive nephrosclerosis (HN ) criteria for HN. From these figures, the adjusted is the second most common cause of end-stage renal prevalence of HN was only 1.5-13.5%. Of patients disease (ESRD) in Caucasians (21% incidence) and that could not be phenotyped for HN, 14 were misdiathe leading cause of ESRD in African Americans (34% gnosed, 14 had urine prot:creat >2.0, and insufficient incidence). Multiple studies demonstrate an even data were available in the remainder. Four patients greater disparity in the rate of renal disease progression underwent renal biopsy, but histology from only one due to hypertension in African Americans compared was consistent with HN. If the HN phenotype definito Caucasians with equivalent blood pressures [3, 4] . tions are revised to exclude 'hypertension preceding Importantly, increased risk to African Americans for renal dysfunction', or proteinuria limits, then 44/100 hypertension-induced ESRD persists even after statistand 39/91 patients respectively satisfy clinical phenoical correction for environmental co-factors [5], sugtyping parameters for HN.
gesting a role for genetic predisposition to ESRD from Conclusions. (i) We provide the strongest evidence to hypertension. A genetic risk for hypertension-related renal disease is also supported by studies demonstrating granting consent were mental impairment that prevented Americans [6, 7] , and to a lesser extent in Caucasians comprehension of the questions, or language barriers.
[8].
The total number of patients was initially screened for a suggested that many patients assigned a diagnosis of HN may actually represent a heterogeneous group HN phenotyping criteria with renal artery stenosis, cholesterol microembolization, and other glomerular diseases [13, 14] . Use of ESRD patients were phenotyped for HN according to parasurrogate clinical parameters to diagnose HN in the meters established from two rigorously designed HN pheno-US may almost entirely account for the variability in typing studies [18, 19] . HN phenotype criteria derived from HN prevalence between large ESRD registries Schlessinger et al. [18] included (i) family history of hyperten-( USRDS, 25%; EDTA, 12%; Australia, 9%) [2, 15] . analysis. Furthermore, many patients erroneously diagnosed with HN may have undetected renal diseases from other causes, and may therefore benefit from Results more than anti-hypertensive therapy.
ESRD diagnoses in the study population
Demographic data describing the entire dialysis popu-
Subjects and methods
lation in Northeast Ohio (n=3100), ESRD patients screened to date (n=607), and the subpopulation with Patient population putative HN diagnoses analysed for this study (n= 100) are shown in Table 1 . Notable is the preponderThe initial study population pool included all ESRD patients ance in the screened population of African Americans, from nine haemodialysis units in the north-east Ohio area which primarily reflects the urban location of the (n=3100). Patients while on dialysis were approached by participating dialysis centres. HN was the most trained interviewers, and asked to answer a screening ques-common cause of ESRD in the overall population tionnaire concerning their medical history and family history according to HCFA 2728 forms, with diabetic nephroof renal disease and hypertension. From the population pathy the second most prevalent aetiology of ESRD screened to date (n=908), initial interviews were conducted ( Table 2 ). These data are consistent with the 1999 in 607 consenting patients (73% African American, 25%
Caucasian, 2% other). The most common reasons for not USRDS report, which cites a 24.5% prevalence and tion of kidney diseases other than HN ( Table 5) .
aNorth-east Ohio. bFrom HCFA 2728 forms.
Alternative diagnoses in patients misclassified with HN 26.6% incidence of ESRD due to hypertension [2] , as Although a definitive HN diagnosis requires a diawell as with Bleyer et al. [20] , who noted a 24 and gnostic renal biopsy, only four of the 100 patients in 38% prevalence of ESRD due to hypertension in our series underwent renal biopsy. As defined by the Caucasians and African Americans respectively. The study design, all four patients were assigned the diarelatively high prevalence of hypertensive ESRD in gnosis of HN on HCFA 2728 forms. However, histoour study may reflect the large number of African logy from only one biopsy was consistent with HN. Americans in our study population, as well as the Focal segmental glomerulosclerosis, IgA nephropathy, recognition that HN incidence (according to the HCFA and chronic interstitial nephritis were diagnosed in the database) is increasing, and may now represent a larger other three patients. In addition to these three patients, proportion of the ESRD population.
many other subjects were diagnosed with HN despite clinical information indicating another diagnosis was HN diagnosis by strict phenotyping criteria more appropriate. The complete list of misdiagnosed patients, including the correct diagnoses, is shown From the total pool of ESRD patients with a HCFA in Table 5 . 2728 form-designated diagnosis of HN, 100 subjects were randomly selected for detailed phenotype analysis according to clinical criteria described in Subjects and Introduction of potential biases in the phenotyping methods. Subset phenotype analysis revealed that only process four of 100 subjects satisfied the Schlessinger criteria
Since our long-term goal is to determine HN susceptifor HN (Table 3) . Because the AASK Trial Group bility loci by whole-genome scanning of DNA samples restricted HN phenotype parameters to African from HN probands and siblings [17] , strict phenotypAmericans, the appropriateness of phenotyping noning criteria could disproportionately exclude patients African American patients using these criteria is with a family history of renal disease, and thereby unclear. Hence, AASK criteria were only applied to increase the number of patients to be screened for the 91 African American patients in our ESRD populaadequate statistical power. This was considered tion. Within this cohort, 28 of 91 patients met AASK unlikely, particularly with respect to Schlessinger cricriteria for HN (Table 4) .
teria, because one parameter is a family history of hypertension, which might therefore preferentially Reasons for difficulty phenotyping HN include patients with a family history of renal disease.
To address the possibility of a family history bias, the The reason for the inability to establish a HN phenotype in most patients, using either set of criteria, was prevalence of ESRD family history ( living sibling or parent receiving renal replacement therapy) was cominsufficient data ( Tables 3, 4) , despite exhaustive medical record reviews that included a comprehensive pared in patients with and those without a HN phenotype by Schlessinger or AASK criteria. Of the 30 search of the earliest available records in all patients. cate that adherence to strict phenotyping criteria for eDiagnosis determined by diagnostic renal biopsy. HN will not disproportionately exclude or include fLong history of intravenous drug abuse; serum anti-HIV antibodies and proteinuria prior to starting dialysis.
patients from subsequent genetic evaluation.
gRapid decline of GFR in context of severe hypertension, papilloedema, left ventricular hypertrophy and abdominal aortic aneurysm.
Implications for design of the HN genetic susceptibility
hMonoclonal protein elevation by serum and urine immunoelectrofixation.
study
Prior to obtaining HN phenotyping data using Schlessinger and AASK criteria, our power analysis phenotype criteria=1.5%). Even if data from the AASK criteria is applied to the high-risk African predicted that screening of 2500 ESRD patients would be required to enrol 150 sib pairs concordant for American population, the prevalence of wellphenotyped HN patients was only 13.5% (43.9% prehypertension and HN and 100 sib pairs concordant for hypertension, but discordant for HN, for genetic valence in African Americans from HCFA 2728 forms×28/91 meeting HN phenotype criteria=13.5%). analyses. This calculation was derived from a HN prevalence of 25%, which was obtained from the Using 'corrected' HN prevalence figures derived from Schlessinger criteria, the adjusted estimate is that nearly USRDS database [2] . When patients were screened with Schlessinger HN phenotype criteria, the overall 42 000 ESRD subjects (Caucasian and African American) would need to be screened to obtain 250 prevalence of HN in our ESRD population (Caucasian and African American) was only 1.5% (36.9% preval-affected and discordant sib pairs (24.6% overall HN prevalence (from USRDS)/corrected 1.5% HN ence from HCFA 2728 forms×4/100 meeting HN prevalence×2500 ESRD patients (from power ana-incidence may partly reflect differences in ESRD study populations or renal biopsy frequencies between counlysis)=41 667 ESRD patients). Because screening such a large number of patients would be a difficult task, tries, our data support the additional possibilities that stringency of diagnostic criteria and misdiagnosis conand assuming that HN is rare in the Caucasian population [21] , an alternative approach is to restrict recruit-tribute to phenotype misclassification.
Though abstraction of diagnoses from standardized ment to African Americans that meet AASK criteria. Even this approach would require screening over 6000 forms generated for financial purposes may be adequate for other projects, one conclusion from our African American patients to obtain the requisite sample size (33.8% HN prevalence in African study is that information from HCFA 2728 forms is inadequate for diagnosing HN. In contrast to other Americans ( USRDS)/corrected 13.5% HN prevalence×2500 ESRD patients (from power ana-diseases that can be definitively phenotyped clinically, HN requires a biopsy, but is generally a diagnosis of lysis)=6259 African American ESRD patients). Although screening 6000 African American ESRD exclusion in the US, often based on no criteria other than co-existing ESRD and hypertension in the absence subjects is more feasible than screening 42 000 ESRD patients with multiple ethnicities, it is clear that identi-of other known renal diseases. To highlight the subjectivity of diagnosing HN clinically, Perneger et al.
[26 ] fication of HN susceptibility genes by either strategy can only be reasonably accomplished in a multi-centre noted that US physicians are twice as likely to diagnose HN in an African American patient compared to a trial design.
Caucasian patient with an otherwise identical case history. Our data are consistent with this finding,
Discussion
inasmuch as 73% of our dialysis patient population is African American, yet 93% of the subjects with insufficient data or incorrect diagnosis of HN were Recent studies indicate that HN may be the most common cause of ESRD, particularly within the African American, and the prevalence of HN by HCFA 2728 forms was approximately twice as great in African African American population [2, 21] . Although blood pressure control is important, anti-hypertensive Americans compared to Caucasians (see Table 2 ).
Because the HN cohort contained few Caucasian subtherapy alone is often insufficient to prevent HN progression to ESRD [21] , suggesting that additional jects, the conclusions of this study may be applicable only to African Americans, and additional studies with factors participate in progressive HN pathogenesis. Published data support the premise that HN suscepti-larger numbers of Caucasians will be necessary to validate results in this ethnic group. bility genes regulate renal tissue injury in response to hypertension. The HDFP and MRFIT trials showed
The lower prevalence of HN compared to the HN prevalence derived from HCFA 2728 forms resulted that loss of kidney function was greater in African Americans than in Caucasians, despite comparable primarily from application of strict surrogate clinical criteria to our prevalent ESRD population. In many levels of diastolic blood pressure [3, 22] . Secondary analyses from the MDRD study demonstrated that, cases in which the HN phenotype could not be established, we speculate that HN was diagnosed by default after controlling for baseline co-variables, the rate of GFR decline was approximately 1 ml/min/year greater in ESRD patients with undiagnosed renal diseases other than HN and secondary hypertension. in African Americans compared to Caucasians with equivalent mean arterial pressures greater than Inaccuracy of HCFA 2728 form diagnoses also raises the possibility of 'false negative' HN patients. Since 98 mmHg [4] , suggesting that susceptibility gene effects may only be apparent when blood pressure control is the study was designed to recruit only patients with presumed HN, the false negative frequency could not not optimal in at-risk African Americans. Finally, multiple studies have demonstrated a familial risk of be calculated. However, because most reports in the HN literature indicate that over-diagnosis is the major ESRD from hypertension [6-8,16 ], suggesting that family-based genetic approaches may enhance the problem [14, 18] , the number of false negatives is likely to be small. probability of HN susceptibility gene discovery.
We have initiated a trial that aims to identify HN Although a significant rate of misdiagnosis was detected in our study, the most common problem with susceptibility gene(s) using two different sets of clinical criteria that best characterize the HN phenotype HN phenotyping was insufficient data. Even when all medical records were exhaustively reviewed, all dia- [18, 19] . When these phenotyping parameters were applied to a dialysis population, the diagnosis of HN gnostic criteria could not be fulfilled in most cases, since many patients presented with advanced renal could not be confirmed in most patients, a finding consistent with divergent estimates of HN incidence disease, and had few diagnostic tests prior to starting dialysis. To avoid exclusion of true HN patients, one that have resulted from differences in diagnostic criteria [14, 15] . At one extreme are prospective, longitudinal could consider loosening the clinical criteria. For example, if 'hypertension preceding renal dysfunction' studies of hypertensive patients [23-25], which conclude that the incidence of HN is negligible. At the is omitted from the Schlessinger HN phenotype definition, 44 of 100 patients then satisfy clinical phenotype other extreme are USRDS figures, which indicate that HN is the most common cause of ESRD, with an criteria for HN, rather than four of 100 with the original, more stringent criteria. However, revising the incidence of 26.6% [2] . While this disparity in HN Schlessinger criteria could include patients with second-component to multiple renal diseases. Based upon the results of this study, we conclude that successful identiary hypertension from renovascular or parenchymal renal disease to be erroneously included in the HN fication of HN susceptibility genes will require either screening a very large number of ESRD patients for a group. Since Bleyer et al. [20] demonstrated a strong correlation between atherosclerosis and hypertensive clinically defined HN phenotype or a prospective trial of biopsy-proven HN subjects. Either strategy is ESRD, and 20 of 44 patients meeting the revised Schlessinger criteria for HN also had a history of beyond the scope of what can be accomplished in our own patient population, and will therefore require a atherosclerosis (data not shown), many of these patients may have renovascular or atheroembolic renal multi-centre effort. disease, rather than HN. If the AASK Trial-based HN phenotype is revised to omit the 'urine protein:creatin-Acknowledgements. This work was supported by grants from the ine ratio <2' criterion, 39 of 91 patients would then National Institutes of Health (DK54644, DK54178, DK38558, satisfy the criteria for HN, compared to 28 of 91 when DK51472, DK02281, DK57329), Northeast Ohio chapter of the American Heart Association, Central Ohio Diabetes Association, the proteinuria limit is considered. Nephrotic-range Leonard Rosenberg Foundation, Juvenile Diabetes Foundation, and proteinuria has been reported in patients with biopsyBaxter Extramural Grant Program. Portions of this work were proven HN [27] , which would justify revision of the presented at the 32nd Annual American Society of Nephrology proteinuria requirement in the HN phenotype. meeting, Miami, FL, 1999. Dr Schelling is an Established However, proteinuria generally does not exceed Investigator of the American Heart Association. 0.5 g/day [21] , and the retrospective study design in the biopsy case series [27] is therefore likely to be biased toward selection of patients with a biopsy
